

**Adult CIRB – Early Phase Emphasis  
Meeting Agenda**

**Tuesday, January 2, 2018  
10:00 am – 12:40 pm (Eastern)**

---

**I Initial Review**

**10166**, A Phase 2 Study of Atezolizumab and Cobimetinib in PD-1/PD-L1 Inhibitor Resistant or Refractory Non-Small Cell Lung Cancer (Protocol Version Date 11/09/17)

---

**II Unanticipated Problem Review**

**EAY131 (MATCH)**, Molecular Analysis for Therapy Choice (Protocol Version Date 07/19/17)

---

**III Continuing Review**

**10009**, A Phase 1b study of the anti-PD1 antibody Pembrolizumab in combination with the histone deacetylase inhibitor, Entinostat for treatment of patients with myelodysplastic syndromes after DNA methyltransferase inhibitor therapy failure (Protocol Version Date 04/25/17)

---

**IV Continuing Review**

**10015**, A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients with Unresectable or Metastatic Epithelioid Hemangioendothelioma (Protocol Version Date 03/22/17)

---

**V Continuing Review**

**9825**, A Phase 2 Study of olaparib and cediranib for the treatment of recurrent ovarian cancer (Protocol Version Date 10/02/17)

---

**VI Continuing Review**

**9855**, A Phase 2 Study of CDX-011 (glembatumumab vedotin) for Metastatic Uveal Melanoma (Protocol Version Date 03/23/17)

---

**VII Continuing Review**

**9824**, A Phase 1 Study of alisertib (MLN8237) in combination with mFOLFOX in gastrointestinal tumors (Protocol Version Date 03/24/16)

---

**VIII Continuing Review**

**A071401**, Phase II Trial Of SMO/AKT/NF2 Inhibitors In Progressive Meningiomas With SMO/AKT/NF2 Mutations (Protocol Version Date 05/01/17)

---

**IX**                      **Continuing Review**

**10013**, Randomized Phase 2 Study of Neoadjuvant Chemotherapy, Carboplatin and Paclitaxel, with or without Atezolizumab in Triple Negative Breast Cancer (TNBC) (Protocol Version Date 05/26/17)

---

---